Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score

Philip Went, Claudio Agostinelli, Andrea Gallamini, Pier Paolo Piccaluga, Stefano Ascani, Elena Sabattini, Francesco Bacci, Brunangelo Falini, Teresio Motta, Marco Paulli, Tullio Artusi, Milena Piccioli, Pier Luigi Zinzani, Stefano A. Pileri

Research output: Contribution to journalArticlepeer-review


Purpose: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). Patients and Methods: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). Results: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation- associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 ≥ 80%. This score was associated with the patient outcome (P <.0001) and was found to be more robust than PIT (P = .0043) in the present series. Conclusion: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient-and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.

Original languageEnglish
Pages (from-to)2472-2479
Number of pages8
JournalJournal of Clinical Oncology
Issue number16
Publication statusPublished - Jun 1 2006

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Marker expression in peripheral T-cell lymphoma: A proposed clinical-pathologic prognostic score'. Together they form a unique fingerprint.

Cite this